Core Viewpoint - Rosen Law Firm is reminding purchasers of Lineage, Inc. common stock about the September 30, 2025 lead plaintiff deadline for a class action lawsuit related to the company's July 2024 IPO [1]. Group 1: Class Action Details - Investors who purchased Lineage common stock may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by September 30, 2025 [3]. - The lawsuit claims that the registration statement was false and/or misleading, failing to disclose significant issues affecting Lineage's business operations and financial results [5]. Group 2: Allegations Against Lineage - The lawsuit alleges that Lineage experienced a sustained weakening in customer demand due to increased cold-storage supply and destocking of excessive inventory by customers [5]. - It is claimed that Lineage implemented unsustainable price increases prior to the IPO, which could not be maintained in the face of weakening demand [5]. - The company reportedly could not counteract adverse trends through operational efficiencies or competitive advantages, leading to stagnant or falling revenue, occupancy rates, and rent prices [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. - Rosen Law Firm has been recognized for its leadership in securities class action settlements, ranking No. 1 in 2017 and consistently in the top 4 since 2013 [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Biohaven Ltd. securities during the specified Class Period of the upcoming lead plaintiff deadline on September 12, 2025, for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought Biohaven securities between March 24, 2023, and May 14, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by the September 12, 2025 deadline [2]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time and being ranked No. 1 for the number of settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3]. Group 3: Case Allegations - The lawsuit alleges that Biohaven made false and misleading statements regarding the regulatory prospects of its drug troriluzole for treating spinocerebellar ataxia and the efficacy of BHV-7000 for bipolar disorder, which were overstated [4]. - The lawsuit claims that these misrepresentations likely had a significant negative impact on Biohaven's business and financial condition once the truth was revealed, resulting in investor damages [4].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Encompass Health Corporation due to allegations of materially misleading business information [1] Group 1: Investigation and Allegations - The investigation is prompted by an article published by The New York Times, which reported serious incidents of patient harm and below-average performance on key safety measures at Encompass Health's rehab hospitals [3] - Following the publication of the article, Encompass Health's stock price dropped by 10.3% on July 15, 2025 [3] Group 2: Class Action Details - Investors who purchased Encompass Health securities may be entitled to compensation through a class action lawsuit, with no out-of-pocket fees due to a contingency fee arrangement [2] - Interested investors can join the class action by submitting a form or contacting the Rosen Law Firm directly [2] Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements and recognition in the field [4] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Encompass Health Corporation due to allegations of materially misleading business information [1] Group 1: Legal Action and Investor Rights - Shareholders of Encompass Health may be entitled to compensation through a class action without any out-of-pocket fees, as the Rosen Law Firm prepares to seek recovery of investor losses [2] - Investors can join the prospective class action by submitting a form or contacting the law firm directly [2] Group 2: Company Performance and Market Reaction - A New York Times article highlighted serious incidents of patient harm and below-average performance on key safety measures at Encompass Health, leading to a 10.3% drop in the company's stock price on July 15, 2025 [3] Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements and recognition in the field, including being ranked No. 1 for securities class action settlements in 2017 [4] - The firm has recovered hundreds of millions of dollars for investors, with over $438 million secured in 2019 alone [4]

Core Viewpoint - Rosen Law Firm is reminding purchasers of XPLR Infrastructure, LP common units of a class action lawsuit with a lead plaintiff deadline of September 8, 2025, for those who bought units between September 27, 2023, and January 27, 2025 [1] Group 1: Class Action Details - Investors who purchased XPLR common units during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6] - Investors wishing to serve as lead plaintiff must file with the Court by September 8, 2025 [3] Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [4] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time, and has recovered hundreds of millions for investors [4] - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020 [4] Group 3: Case Allegations - The lawsuit alleges that XPLR made false and misleading statements regarding its operations as a yieldco, including struggles to maintain operations and the unsustainability of its business model [5] - It is claimed that XPLR entered financing arrangements while downplaying risks, which ultimately led to a halt in cash distributions to investors [5] - The lawsuit asserts that the public statements made by the defendants were materially false and misleading, resulting in investor damages when the truth was revealed [5]

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Encompass Health Corporation due to allegations of materially misleading business information [1] Group 1: Investigation and Allegations - The investigation is prompted by an article from The New York Times highlighting serious incidents of patient harm and below-average performance on key safety measures at Encompass Health's rehab hospitals [3] - Following the publication of the article, Encompass Health's stock price dropped by 10.3% on July 15, 2025 [3] Group 2: Class Action Details - Investors who purchased Encompass Health securities may be entitled to compensation through a class action lawsuit without any out-of-pocket fees [2] - The Rosen Law Firm is preparing a class action to seek recovery of investor losses [2] Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time [4] - The firm has been ranked in the top 4 for securities class action settlements since 2013 and recovered hundreds of millions of dollars for investors, including over $438 million in 2019 [4]

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of LifeMD, Inc. securities between May 7, 2025, and August 5, 2025, due to alleged misleading statements and failure to disclose critical information regarding the company's competitive position and customer acquisition costs [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that LifeMD's defendants made materially false and misleading statements about the company's competitive position and financial guidance, particularly regarding customer acquisition costs in the RexMD segment and the sale of obesity treatment drugs [5]. - Investors who purchased LifeMD securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Next Steps for Investors - Interested investors can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6]. - A lead plaintiff must be appointed by October 27, 2025, to represent other class members in the litigation [3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Encompass Health Corporation due to allegations of materially misleading business information issued to the public [1] Group 1: Investigation and Allegations - The investigation is prompted by an article published by The New York Times on July 15, 2025, which highlighted serious incidents of patient harm and below-average performance on key safety measures at Encompass Health's rehab hospitals [4] - Following the publication of the article, Encompass Health's stock price experienced a significant decline of 10.3% on the same day [4] Group 2: Class Action and Compensation - Shareholders who purchased Encompass Health securities may be entitled to compensation through a class action lawsuit, with no out-of-pocket fees or costs due to a contingency fee arrangement [2] - Interested parties can join the prospective class action by submitting a form or contacting the Rosen Law Firm directly [3] Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time and consistently ranking in the top 4 for securities class action settlements since 2013 [5] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering significant amounts for its clients [5]

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Quantum Corporation due to allegations of materially misleading business information [1] Group 1: Investigation and Legal Action - Shareholders of Quantum Corporation may be entitled to compensation through a class action lawsuit without any out-of-pocket fees [2] - The Rosen Law Firm is preparing a class action to seek recovery of investor losses [2] Group 2: Company Developments - On August 18, 2025, Quantum Corporation's CFO, Lewis Moorehead, resigned amid an internal accounting review related to revenue recognition practices [3] - Following the announcement of the CFO's resignation, Quantum's stock price fell by $0.61 per share, or 8.2%, closing at $6.83 per share on August 19, 2025 [3] Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time [4] - The firm has been ranked in the top 4 for securities class action settlements since 2013 and recovered hundreds of millions of dollars for investors, including over $438 million in 2019 [4]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Fiserv, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - The Class Period for the Fiserv common stock is from July 24, 2024, to July 22, 2025, inclusive [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A lead plaintiff must file a motion with the Court by September 22, 2025, to represent other class members [2] Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions [3] - Rosen Law Firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [3] - The firm has consistently ranked in the top 4 for securities class action settlements since 2013, recovering hundreds of millions for investors [3] Group 3: Case Allegations - The lawsuit alleges that Fiserv made false and misleading statements regarding its Clover platform and the forced migration of Payeezy merchants [4] - It is claimed that Clover's revenue growth was artificially inflated due to these forced conversions, masking a slowdown in new merchant business [4] - The lawsuit asserts that many former Payeezy merchants switched to competitors due to Clover's high pricing and compatibility issues, leading to a significant slowdown in Clover's growth [4]